All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

amprenavir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
HIV protease inhibitors	200	161814-49-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: amprenavir agenerase angenerase samprenavir	; RN refers to (3S-(3R*(1S*,2R*)))-isomer; fosamprenavir is a prodrug Molecular weight: 505.63 Formula: C25H35N3O6S CLOGP: 3.29 LIPINSKI: 1 HAC: 9 HDO: 3 TPSA: 131.19 ALOGS: -4.01 ROTB: 11 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
1.20	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.04 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	67.81 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	35 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	2.484		Moderate	0.72
caco2-efflux	Caco-2 efflux ratio (BA/AB)	4.055		Moderate	0.72
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	48.306	10^-6 cm/s	Moderate	0.72
dh-clint	Dog hepatocyte intrinsic clearance	12.618	uL/min/10^6 cells	Moderate	0.72
dppb	Dog plasma protein binding (% unbound)	17.090	%	Moderate	0.72
fcs-ppb	Fetal calf serum protein binding (% unbound)	28.520	%	Moderate	0.72
herg	hERG pIC50	4.500	pIC50	Moderate	0.72
hh-clint	Human hepatocyte intrinsic clearance	29.444	uL/min/10^6 cells	Moderate	0.72
hlm-clint	Human liver microsomal intrinsic clearance	214.783	uL/min/mg protein	Moderate	0.72
hppb	Human plasma protein binding (% unbound)	18.120	%	Moderate	0.72
kinase-safety-class	ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,TEK	21
kinase-selectivity-class	AURKA,AXL,GRK2,TEK	4
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	13.709		High	1
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	7.870		Moderate	0.72
mh-clint	Mouse hepatocyte intrinsic clearance	133.045		Moderate	0.72
mppb	Mouse plasma protein binding (% unbound)	13.250		Moderate	0.72
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	47.534		Moderate	0.72
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	25.090	%	Moderate	0.72
rat-kpuu-brain	Rat brain Kpuu	0.024	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	180.717	uL/min/10^6 cells	Moderate	0.72
rh-fuinc	Rat hepatocyte fraction unbound in incubation	73.500	%	Moderate	0.72
rppb	Rat plasma protein binding (% unbound)	15.580	%	Moderate	0.72
solubility-dd	Solubility at pH 7.4 in DMSO	222.844	uM	Moderate	0.72

Approvals:

Date	Agency	Company	Orphan
Oct. 20, 2000	EMA
April 15, 1999	FDA	GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J05AE05	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Protease inhibitors
FDA MoA	N0000000246	HIV Protease Inhibitors
MeSH PA	D000084762	Viral Protease Inhibitors
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000904	Antibiotics, Antitubercular
MeSH PA	D000995	Antitubercular Agents
MeSH PA	D000998	Antiviral Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D011480	Protease Inhibitors
MeSH PA	D017320	HIV Protease Inhibitors
MeSH PA	D019380	Anti-HIV Agents
MeSH PA	D044966	Anti-Retroviral Agents
FDA EPC	N0000175889	Protease Inhibitor
FDA MoA	N0000182141	Cytochrome P450 3A4 Inhibitors
FDA MoA	N0000185506	Cytochrome P450 3A4 Inducers
FDA MoA	N0000191264	P-Glycoprotein Inducers
CHEBI has role	CHEBI:22587	antiviral agent
CHEBI has role	CHEBI:35660	HIV protease inhibitor
CHEBI has role	CHEBI:36044	antiviral drug
CHEBI has role	CHEBI:64946	anti-HIV agent

Related Drugs by ATC class:

J05AE Protease inhibitors 10 drugs

atazanavirdarunavirensitrelvirfosamprenavirindinavirnelfinavirnirmatrelvirritonavirsaquinavirtipranavir

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Human immunodeficiency virus infection	indication	86406008	DOID:526
Prevention of HIV Infection after Exposure	off-label use
Acquired hemolytic anemia	contraindication	4854004
Hypercholesterolemia	contraindication	13644009
Myocardial infarction	contraindication	22298006	DOID:5844
Hereditary factor VIII deficiency disease	contraindication	28293008	DOID:12134
Hypertensive disorder	contraindication	38341003	DOID:10763
Hereditary factor IX deficiency disease	contraindication	41788008	DOID:12259
Hemolytic anemia	contraindication	61261009	DOID:583
Chronic type B viral hepatitis	contraindication	61977001
Blood coagulation disorder	contraindication	64779008	DOID:1247
Lipodystrophy	contraindication	71325002	DOID:811
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Kidney stone	contraindication	95570007
Chronic hepatitis C	contraindication	128302006
Liver function tests abnormal	contraindication	166603001
Disease of liver	contraindication	235856003	DOID:409
Familial hypercholesterolemia - homozygous	contraindication	238078005
Hypertriglyceridemia	contraindication	302870006
Cardiovascular event risk	contraindication	395112001
Autoimmune hemolytic anemia	contraindication	413603009	DOID:718
Breastfeeding (mother)	contraindication	413712001
Disorder of coronary artery	contraindication	414024009
Obesity	contraindication	414916001	DOID:9970
Ketoacidosis in diabetes mellitus	contraindication	420422005	DOID:1837
Smokes tobacco daily	contraindication	449868002
Vitamin K Deficiency Induced Hypoprothrombinemia	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.6	acidic
pKa2	1.64	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Thromboxane-A synthase	Enzyme	P24557	THAS_HUMAN		IC50	5.17		DRUG MATRIX
Cathepsin D	Enzyme	P07339	CATD_HUMAN		IC50	4.82		CHEMBL
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		IC50	6		DRUG MATRIX
Pol polyprotein	Enzyme		Q72874_9HIV1	INHIBITOR	Ki	10.40		CHEMBL	CHEMBL
Gag-Pol polyprotein	Polyprotein		POL_HV1BR					WOMBAT-PK
Protease	Enzyme		Q9YQ12_9HIV1		Ki	10.44		CHEMBL
Protease	Enzyme		O90781_9PLVG		Ki	10.52		CHEMBL
Protease	Enzyme		Q9YQ30_9PLVG		Ki	9.82		CHEMBL

External reference:

ID	Source
4021158	VUID
N0000148609	NUI
D00894	KEGG_DRUG
228655	RXNORM
C0754188	UMLSCUI
CHEBI:40050	CHEBI
478	PDB_CHEM_ID
CHEMBL116	ChEMBL_ID
DB00701	DRUGBANK_ID
C095108	MESH_SUPPLEMENTAL_RECORD_UI
12681	IUPHAR_LIGAND_ID
7751	INN_ID
5S0W860XNR	UNII
65016	PUBCHEM_CID
29919	MMSL
8067	MMSL
d04428	MMSL
4021158	VANDF
007752	NDDF
116088006	SNOMEDCT_US
387006009	SNOMEDCT_US
5S0W860XNR	INXIGHT DRUGS

Pharmaceutical products:

None